Startup Dossier
Signadori Bio
Signadori Bio is a preclinical-stage biotech developing an off-the-shelf in vivo engineered monocyte immunotherapy platform designed to treat solid tumors by reprogramming innate immune cells directly inside the body.
active
Typestartup
SectorBioTech
LocationParis
About
Signadori Bio is a preclinical-stage biotech developing an off-the-shelf in vivo engineered monocyte immunotherapy platform designed to treat solid tumors by reprogramming innate immune cells directly inside the body.
Structural DNA
Legal Name
Signadori Bio
SIREN
928169697
Founders & Team
Funding Lineage
Seed
3 investors
€11.1M
May 2026